Tag - NANO

Developments

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non...

January 21, 2025

Feature

Nanobiotix pioneering nanomedicine in new paradigm against cancer

By Len Zehrs France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients. “What differentiates us is that we...

May 15, 2018

Tag - NANO

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix pioneering nanomedicine in new paradigm against cancer

General

More